Rhumbline Advisers Sells 34,159 Shares of Edwards Lifesciences Corporation $EW

Rhumbline Advisers lessened its stake in Edwards Lifesciences Corporation (NYSE:EW) by 3.0% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,095,995 shares of the medical research company’s stock after selling 34,159 shares during the quarter. Rhumbline Advisers’ holdings in Edwards Lifesciences were worth $85,718,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of EW. Brighton Jones LLC purchased a new stake in Edwards Lifesciences in the 4th quarter worth $266,000. Avantax Advisory Services Inc. increased its holdings in shares of Edwards Lifesciences by 10.7% in the first quarter. Avantax Advisory Services Inc. now owns 10,707 shares of the medical research company’s stock worth $776,000 after purchasing an additional 1,032 shares during the last quarter. HB Wealth Management LLC lifted its position in shares of Edwards Lifesciences by 34.9% in the first quarter. HB Wealth Management LLC now owns 21,562 shares of the medical research company’s stock worth $1,563,000 after buying an additional 5,577 shares in the last quarter. Empirical Finance LLC lifted its position in shares of Edwards Lifesciences by 2.2% in the first quarter. Empirical Finance LLC now owns 21,195 shares of the medical research company’s stock worth $1,536,000 after buying an additional 461 shares in the last quarter. Finally, LPL Financial LLC boosted its stake in Edwards Lifesciences by 23.9% during the first quarter. LPL Financial LLC now owns 324,351 shares of the medical research company’s stock valued at $23,509,000 after buying an additional 62,671 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Up 1.1%

Shares of EW opened at $85.02 on Monday. Edwards Lifesciences Corporation has a twelve month low of $65.94 and a twelve month high of $87.21. The company has a market cap of $49.34 billion, a P/E ratio of 12.23, a P/E/G ratio of 3.97 and a beta of 1.03. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The company’s fifty day simple moving average is $78.80 and its 200-day simple moving average is $78.09.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. The firm had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. During the same period in the previous year, the company earned $0.67 EPS. The firm’s revenue for the quarter was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. As a group, analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on EW. Wall Street Zen cut Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a report on Monday, September 29th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Wednesday, October 8th. Sanford C. Bernstein reissued a “market perform” rating and issued a $90.00 price objective on shares of Edwards Lifesciences in a research note on Monday, November 3rd. Evercore ISI boosted their target price on shares of Edwards Lifesciences from $88.00 to $92.00 and gave the stock an “outperform” rating in a report on Friday, October 31st. Finally, Wells Fargo & Company upped their target price on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the company an “overweight” rating in a research report on Thursday, August 7th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $91.39.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,020 shares of the company’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $82.55, for a total value of $84,201.00. Following the transaction, the vice president owned 22,002 shares of the company’s stock, valued at $1,816,265.10. This represents a 4.43% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction on Monday, November 10th. The stock was sold at an average price of $83.08, for a total value of $1,080,040.00. Following the completion of the sale, the chief financial officer owned 39,898 shares in the company, valued at approximately $3,314,725.84. The trade was a 24.58% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.